

1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Li

Liebmann-Vinson et al.

SERIAL NO.:

10/660,760

GROUP:

1712

FILING DATE:

September 12, 2003

EXAMINER:

FOR:

METHODS OF SURFACE MODIFICATION OF A FLEXIBLE

SUBSTRATE TO ENHANCE CELL ADHESION

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE
OR CONCURRENTLY WITH A RULE 53(d) CPA APPLICATION
OR WITH A RULE 1.114 RCE APPLICATION)

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u>

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO/SB/08A(s), attached hereto.

II. <u>COPIES</u> (check at least one box)

- a. Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b. Some or all of the documents listed on the PTO/SB/08A are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

consideration.

The following additional information is provided for the Examiner's

D

<u>FEES</u>

IV.	\boxtimes		IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b): cone box)
	a.		within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's and CPA's).
	b.		within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.
	c.		concurrently with the filing of a Continued Prosecution Application under 37 C.F.R. § 1.53(d) or concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
	d.	\boxtimes	before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.
		,	In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge Deposit Account No. 02-1666 in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
V.			IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c): one box)
	1.97(c)(1)) or	iling date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 a. § 1.97(c)(2)).
	a.		No statement; therefore, a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
			OI .
	b.		See the statement below. No fee is required.

STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box) The undersigned hereby states that a. each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or b. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. Some of the items of information were cited in a communication from a c. foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement. VII. PAYMENT OF FEES (check one box) A check in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee. No fee is required. M Please charge Deposit Account No. 02-1666 in the amount required by 37 C.F.R. § 1.17(p) for the above-indicated fee. A triplicate copy of this paper is attached.

VI.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-1666.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future

replies, to charge payment or credit any overpayment to Deposit Account No. 02-1666 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees. Respectfully submitted, Becton, Dickinson and Company Date: Ebruary 33, 2 1 Becton Drive, MC 089 Franklin Lakes, New Jersey 07417 (201) 847-6659 Enclosures: ▼ PTO/SB/08A Documents Foreign Search Report Fee Other: (Rev. 01/03/03 I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, MAIL STOP DD, P.O. BOX 1450, ALEXANDRIA, VA

Doc. No. 74881

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper wirk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

FEB 2 6 2004

Sheet

j.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Complete if Known					
Application Number	10/660,760				
Filing Date	September 12, 2003				
First Named Inventor	LIEBMANN-VINSON et al				
Art Unit					
Examiner Name					
Attorney Docket Number	P-5838				

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (if known)}			r igures Appear
		^{US-} 6395506	05-28-2002	Pitner et al.	
		^{US-} 6218178	04-17-2001	Banes	
		^{US-} 6107083	08-22-2000	Collins et al.	
		^{US-} 6080574	06-27-2000	Berndt	
·		^{US-} 6057150	05-02-2000	Lee et al.	
		^{US-} 6048723	04-11-2000	Banes	
		^{US-} 6037141	03-14-2000	Banes	
		US- 5998517	12-07-1999	Gentle et al.	
		^{US-} 5567598	10-22-1996	Stitt et al.	
		^{US-} 5278063	01-11-1994	Hubbell et al	
		^{US-} 4851521	07-25-1989	della Valle et al	
		^{US-} 4839280	06-13-1989	Banes	
		^{US-} 4822741	04-18-1989	Banes	
		^{US-} 4789601	12-06-1988	Banes	
		US-			
	_	US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
						Ļ
						╟
		40.00.00.00.00.00.00.00.00.00.00.00.00.0				╄
						Г

Examiner	Date	
Signature	Considered	
•		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031

A	ler the Paperwork Red	luction A	ct of 1995, no persons ar		Approved for use through 04/30/2003. OMB 0651-003 and Trademark Office; U.S. DEPARTMENT OF COMMERC of information unless it contains a valid OMB control number	Ε
					Complete if Known	\
	e for form 14 9/PTO			Application Number	10/660,760	_
INFO	ORMATION	I DIS	CLOSURE	Filing Date	September 12, 2003	_
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	LIEBMANN-VINSON et al	
	(Use as many she	ote se n	acassani)	Art Unit		
	(Ose as many sne	7013 a3 11	ocessary,	Examiner Name		
Sheet	2	of	5	Attorney Docket Number	P-5838	/

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BRANDLEY et al., Anal. Biochem. (1988) 172:270.	
		CHAUDHURY et al., Langmuir, (1991) 7:1013-1025.	
		CHOI et al., Biomaterials (1999) 20:409-417.	
		COSTELLO et al., Macromolecules (1987) 20:2819-2828.	
		COUCHMAN et al., J.Cell Biol.,(1982) 93:402-410.	
		EFIMENKO et al., J. Colloid Interface Sci., (2002) 254(2):306-315.	
		EFIMENKO et al., Adv. Matl., (2001) 13:1560-63.	
		GENZER et al., Science (2000) 290:2130-33.	
		GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.	
		GUTSCHE et al., Biomaterials (1996) 17:387-393.	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE action Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known		
Application Number	10/660,760	
Filing Date	September 12, 2003	
First Named Inventor	LIEBMANN-VINSON et al	
Art Unit		
Examiner Name		
Attorney Docket Number	P-5838	
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date September 12, 2003 First Named Inventor LIEBMANN-VINSON et al Art Unit Examiner Name

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
nitials*	No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HERN et al., J. Biomed. Mater. Res. (1998) 39:266-276.	
		HSIUE et al., J. Biomed. Mater. Res., (1998) 42:134-147.	
		KIM et al., Ann. Surgery (1998) 228:8-13.	
		KLEINMAN, et al., Biochem. Biophys. Res. Commun. (1976) 72:426-432.	
		LATEEF et al., Biomaterials, (2002) 23: 3159-3168.	
		LEE et al., Journal of Polymer Science: Part A: Polymer Chemistry, (1996) 34:141-148.	
		LU et al., Biomaterials (2000) 21: 1595- 1605.	
		MADIHALLY et al., Biomaterials. (1999) 20:1133-42	
		MOONEY et al., Biomaterials (1996) 17:1417-1422.	
		MURAKAMI et al., J. Colloid & Interface Science (1998) 200:192-94.	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

FEB 2 6 2004

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
b a collection of information unless it contains a valid OMB control number.

	e for CET 443/PTO		x or 1000; no porcono ar	Complete if Known		
Cabound	17407			Application Number	10/660,760	
INFO	DRMATION	DIS	CLOSURE	Filing Date	September 12, 2003	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	LIEBMANN-VINSON et al	
	(Use as many she	ote se n	ococcand	Art Unit		
	(Use as many site	oto as n		Examiner Name		
Sheet	4	of	5	Attorney Docket Number	P-5838	

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		OXLEY et al. Biomaterials (1993) 14:1064-1072.	
		PEARLSTEIN, E., Nature (1976) 262:497-500.	
		PINILLA et al., Meth. Molec. Biol., (1996) 66:171-179.	
		RANUCCI et al., Tissue Engineering (1999) 5: 407-420.	
		SAAD et al., J. Biomed. Res. (1996) 32:355-366.	
		SILVER et al., Biomaterials, (1999) 20: 1533-1543.	
		SILVER et al., Journal of Biomedical Materials Research (1995) 29:535-548.	
		SINGER et al., J. Cell Biol. (1987) 104:573-584.	
		TORRES et al., Biomaterials (2000) 21:1607-19.	
		VOGLER et al., Journal of Biomedical Materials Research (1987) 21:1197-1211.	

Examiner Signature	Date Considered	
•		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTC/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Substitute by form 14494450				Complete if Known			
Cabbina	RACEMAN			Application Number	10/660,760		
INFORMATION DISCLOSURE				Filing Date	September 12, 2003		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	LIEBMANN-VINSON et al		
(Use as many sheets as necessary)				Art Unit			
				Examiner Name			
Sheet	5	of	5	Attorney Docket Number	P-5838		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		WHANG et al., Polymer (1995) 36:837-842.	
		WU et al., Macromolecules (2001) 34:684-86.	
		ZHANG et al., J. Biomed. Mater. Res., (1999) 45:285-293.	
-			

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.